08:00 , Dec 7, 2015 |  BC Week In Review  |  Clinical News

ANG1005: Interim Phase II data

Interim data from 21 heavily pre-treated breast cancer patients with leptomeningeal carcinomatosis in an open-label, U.S. Phase II trial showed that ANG1005 led to 5 partial responses and 11 cases of stable disease as best...
07:00 , Jun 16, 2014 |  BioCentury  |  Regulation

Signal crossing

FDA's workshop on neurological symptoms in inborn errors of metabolism revealed conflicts between how caregivers would like symptoms assessed and what drug companies need to test to get therapies approved. The June 10 workshop was the...
07:00 , Jun 9, 2014 |  BC Week In Review  |  Clinical News

ANG1005: Phase II started

Angiochem began an open-label, U.S. Phase II trial to evaluate ANG1005 in up to 40 patients with progressive or recurrent HER2-positive breast cancer with brain metastases. Late last month, FDA granted Orphan Drug and Fast...
07:00 , Oct 28, 2013 |  BC Week In Review  |  Clinical News

ANG1005: Phase II started

Angiochem began a U.S. Phase II trial to evaluate ANG1005 in up to 83 patients with recurrent high-grade glioma. Next quarter, Angiochem also plans to start a Phase II trial of ANG1005 in HER2-positive breast...
07:00 , Oct 28, 2013 |  BC Week In Review  |  Clinical News

ANG1005: Additional Phase II data

Angiochem said it will continue to develop ANG1005 based on data from 80 patients with brain metastases arising from metastatic breast cancer in the open-label, North American Phase II GRABM-B trial showing that the compound...
07:00 , Aug 29, 2013 |  BC Innovations  |  Distillery Therapeutics

Indication: Neurology

This week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Neurology Nerve damage Low-density lipoprotein-related protein 1 a-2-macroglobulin receptor (LRP1; CD91); neurotrophic tyrosine...
08:00 , Feb 28, 2013 |  BC Innovations  |  Distillery Techniques

Technology: Drug delivery

Approach Summary Licensing status Publication and contact information Drug delivery Apolipoprotein E (APOE)-derived peptide for drug delivery across the blood brain barrier (BBB) In vitro and mouse studies...
08:00 , Feb 21, 2013 |  BC Innovations  |  Distillery Therapeutics

Indication: Neurology

This week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Neurology Alzheimer's disease (AD) CD36 (GPIV) Mouse studies suggest antagonizing CD36 could help...
08:00 , Dec 10, 2012 |  BC Week In Review  |  Clinical News

GRN1005: Development discontinued

Geron discontinued development of GRN1005 after a planned interim futility analysis of the first 30 evaluable patients with brain metastases arising from metastatic breast cancer in the open-label, North American Phase II GRABM-B trial showed...
07:00 , Mar 12, 2012 |  BioCentury  |  Product Development

Replacing the replacements

GlaxoSmithKline plc is planning to use peptide technology from Angiochem Inc. to develop next-generation enzyme replacement therapies that target the CNS without lessening their effects in the periphery. They could replace current drugs that address...